Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
Clin Transl Allergy
.
2021 Oct 14;11(8):e12067.
doi: 10.1002/clt2.12067.
eCollection 2021 Oct.
Authors
Laura Pini
1
2
,
Cristiano Caruso
3
4
,
Stefania Colantuono
3
,
Diego Bagnasco
5
,
Aoife Maxwell
6
,
Robert G Price
7
,
Peter Howarth
8
,
Giorgio Walter Canonica
9
10
;
Italian investigators of REALITI‐A
Affiliations
1
Respiratory Unit Spedali Civili di Brescia Brescia Italy.
2
Department of Clinical and Experimental Sciences University of Brescia Brescia Italy.
3
Department of Medical and Surgical Sciences Fondazione Policlinico A. Gemelli IRCCS Rome Italy.
4
Università Cattolica del Sacro Cuore Rome Italy.
5
Allergy and Respiratory Diseases IRCCS Policlinico San Martino University of Genoa Genoa Italy.
6
Real World Study Delivery Value Evidence and Outcomes Global Medical GSK Stevenage Hertfordshire UK.
7
Biostatistics R&D GSK Stevenage Hertfordshire UK.
8
Global Medical Global Specialty & Primary Care TA GSK House Brentford Middlesex UK.
9
Department of Biomedical Sciences Humanitas University Milan Italy.
10
Personalized Medicine Asthma and Allergy Clinic Humanitas Research Hospital IRCCS Milan Italy.
PMID:
34691389
PMCID:
PMC8517195
DOI:
10.1002/clt2.12067
No abstract available